tesaglitazar
Small moleculeexperimental
Tesaglitazar is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for the management of type 2 diabetes. — Wikipedia
Clinical trial activity
17 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
17
Phase 3
13
Phase 4
0
Earliest trial started Apr 1, 2002 (NCT00280865)
Timeline
Indications
Studied for
Mechanism of action
PPARA agonist
All Ph3 trials terminated, discontinued due to safety concerns (http://en.wikipedia.org/wiki/Tesaglitazar)
PPARG agonist
All Ph3 trials terminated, discontinued due to safety concerns (http://en.wikipedia.org/wiki/Tesaglitazar)
Chemistry & pharmacology
Loading structure…
SMILES
CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O- Mol. weight
- 408.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTesaglitazar ↗
- ChEMBLCHEMBL282686 ↗
Also known as
- 2-ethoxy-3-(4-((4-(methylsulfonyloxy)phenethyl)oxy)phenyl)propanoic acid
- ar-h039242xx
- ar-h039242xx
- az 242
- az-242
- az-242
- br-44608
- br-44608
- galida
- galida
- (s)-2-ethoxy-3-(4-(2-(4-methylsulphonyloxyphenyl)ethoxy)phenyl)propanoic acid
- (s)-2-ethoxy-3-(4-((4-(methylsulfonyloxy)phenethyl)oxy)phenyl)propanoic acid
- tesaglitazar
- tesaglitazar
- tesaglitazar
- tesaglitazar
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00300105 | Phase 3 | Oct 1, 2005 | AstraZeneca |
| NCT00263965 | Phase 2 | Aug 1, 2005 | AstraZeneca |
| NCT00252837 | Phase 3 | Apr 1, 2005 | AstraZeneca |
| NCT00226330 | Phase 3 | Mar 1, 2005 | AstraZeneca |
| NCT00252876 | Phase 3 | Mar 1, 2005 | AstraZeneca |
| NCT00261352 | Phase 3 | Mar 1, 2005 | AstraZeneca |
| NCT00229710 | Phase 3 | Feb 1, 2005 | AstraZeneca |
| NCT00252772 | Phase 3 | Sep 1, 2004 | AstraZeneca |
| NCT00229684 | Phase 2 | Sep 1, 2004 | AstraZeneca |
| NCT00255541 | Phase 3 | Sep 1, 2004 | AstraZeneca |
| NCT00214565 | Phase 3 | Aug 1, 2004 | AstraZeneca |
| NCT00214591 | Phase 3 | Aug 1, 2004 | AstraZeneca |
| NCT00242372 | Phase 3 | Aug 1, 2004 | AstraZeneca |
| NCT00251940 | Phase 3 | Jul 1, 2004 | AstraZeneca |
| NCT00251953 | Phase 3 | Jul 1, 2004 | AstraZeneca |
| NCT00261417 | Phase 2 | May 1, 2004 | AstraZeneca |
| NCT00280865 | Phase 2 | Apr 1, 2002 | AstraZeneca |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 17 | 17 | 2 | 2002 |
1 organizations
Page 1 / 1